2. Vías de señalización
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

ADC-Related Custom Services

Drug-Linker Conjugates for ADC

Related Products

PDF 0.45 MB

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.

Drug-Linker Conjugates for ADC Isoform Specific Products:

Drug-Linker Conjugates for ADC Isoform Comparison
Cat. No. Nombre del producto Efecto Pureza Chemical Structure
  • HY-128902
    MC-Val-Cit-PAB-vinblastine
    		99.48%
    MC-Val-Cit-PAB-vinblastine is a agent-linker conjugate for ADC with potent antitumor activity by using vinblastine (an microtubule protein inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
    MC-Val-Cit-PAB-vinblastine
  • HY-148436
    Glucocorticoid receptor agonist-2 Ala-Ala-Mal
    Glucocorticoid receptor agonist-2 Ala-Ala-Mal (compound 79) can be used to synthesize anti-inflammatory ADC molecules. Glucocorticoid receptor agonist-2 is an active reference for ABBV-3373.
    Glucocorticoid receptor agonist-2 Ala-Ala-Mal
  • HY-147340
    TL033
    		98.11%
    TL033 is a drug-Linker conjugates for ADC. TL033 contains a linker and bioactive small molecule toxins. TL033 can conjugate with Sacituzumab antibody (anti Trop-2) for synthesizing BT001021. BT001021 has anti-cancer activities against various cancers, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer.
    TL033
  • HY-153263
    (Aminooxy)acetamide-Val-Cit-PAB-MMAE
    (Aminooxy)acetamide-Val-Cit-PAB-MMAE (MMAE 5) is an intermediate used in the synthetic preparation of drug-linker conjugates for ADC. (Aminooxy)acetamide-Val-Cit-PAB-MMAE is conjugated to polyamide via oxime bond formation to form MMAE polyamide conjugate. Then MMAE polyamide conjugate can be conjugated to Trastuzumab, to make ADC.
    (Aminooxy)acetamide-Val-Cit-PAB-MMAE
  • HY-100567
    MAL-di-EG-Val-Cit-PAB-MMAE
    		99.92%
    MAL-di-EG-Val-Cit-PAB-MMAE consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin inhibitor (MMAE).
    MAL-di-EG-Val-Cit-PAB-MMAE
  • HY-132250
    MCC-DM1
    		99.52%
    MCC-DM1 is a agent-Linker Conjugates for ADC such as Anti-CD22-MCC-DM1. MCC-DM1 can be detected in rat and human plasma, feces, and other tissues.
    MCC-DM1
  • HY-170400
    LNK4-S
    LNK4-S is a drug-linker conjugate, that can be used for synthesis of ADC molecule M-VA-EXA and F-VA-EXA.
    LNK4-S
  • HY-126691
    DBCO-PEG4-VC-PAB-DMEA-PNU-159682
    		99.03%
    DBCO-PEG4-VC-PAB-DMEA-PNU-159682, a agent-linker conjugate for ADC, consists the ADC linker DBCO-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682. DBCO-PEG4-VC-PAB-DMEA-PNU-159682 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DBCO-PEG4-VC-PAB-DMEA-PNU-159682
  • HY-13631M
    Gly-Gly-Phe-Gly-NH-O-CO-Exatecan
    Gly-Gly-Phe-Gly-NH-O-CO-Exatecan is a Drug-Linker Conjugates for ADC, consiting of an ADC linker and Exatecan (HY-13631) (topoisomerase I inhibitor). Gly-Gly-Phe-Gly-NH-O-CO-Exatecan can be used for ADC molecues synthesis.
    Gly-Gly-Phe-Gly-NH-O-CO-Exatecan
  • HY-153069
    GGFG-PAB-Exatecan
    		99.71%
    GGFG-PAB-Exatecan consists of an ADC toxin Exatecan (HY-13631) and a linker GGFG-PAB, and can be used as a drug-linker conjugate for the synthesis of ADC molecules.
    GGFG-PAB-Exatecan
  • HY-139326
    NHS-MMAF
    NHS-MMAF is a modified MMAF extracted from patent WO2012143499, intermediat 219. MMAF is a potent tubulin polymerization inhibitor and is used as a antitumor agent
    NHS-MMAF
  • HY-147286
    Ac-Lys-Val-Cit-PABC-MMAE
    		99.94%
    Ac-Lys-Val-Cit-PABC-MMAE is a agent-linker conjugate for ADC. Ac-Lys-Val-Cit-PABC-MMAE contains the ADC linker (peptide Ac-Lys-Val-Cit-PABC) and a potent tubulin polymerization inhibitor MMAE (HY-15162).
    Ac-Lys-Val-Cit-PABC-MMAE
  • HY-164835
    VcMMAE-Deruxtecan
    		98.10%
    VcMMAE-Deruxtecan (SMP-54418) is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule MMAE (HY-15162) (Microtubule inhibitor) and Exatecan (HY-13631) (DNA topoisomerase I inhibitor). VcMMAE-Deruxtecan can be used for ADC synthesis.
    VcMMAE-Deruxtecan
  • HY-160441
    MC-Val-Cit-PAB-Ispinesib
    		99.85%
    MC-Val-Cit-PAB-Ispinesib (Compound 509) is a drug-linker conjugate for ADC, consisting of a cleavable ADC linker and Eg5 inhibitor. MC-Val-Cit-PAB-Ispinesib can be used for the synthesis of antibody-drug conjugates (ADCs).
    MC-Val-Cit-PAB-Ispinesib
  • HY-160015
    CB07-Exatecan
    		98.97%
    CB07-Exatecan is an ADC drug-Linker conjugate that can be used for the synthesis of ADCs. ADC conjugated with CB07-Exatecan and trastuzumab inhibits the growth of HER2-positive cancer cells. CB07-Exatecan can be used in cancer research.
    CB07-Exatecan
  • HY-112616
    NAMPT inhibitor-linker 2
    		99.35%
    NAMPT inhibitor-linker 2 is a agent-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker. ADC-4 consists of an NAMPT inhibitor-linker 2 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526, with IC50s of <7 pM and 40 pM, respectively.
    NAMPT inhibitor-linker 2
  • HY-148426
    OSu-PEG4-VC-PAB-MMAE
    		98.91%
    OSu-PEG4-VC-PAB-MMAE involves in GDP-FAmP4MMAE (Monomethylauristatin E) synthesis, which is for GDP label via site-specific conjugation.
    OSu-PEG4-VC-PAB-MMAE
  • HY-174279
    MCC-AAQ-Exa
    MCC-AAQ-Exa is a drug-linker conjugates for ADC, obtained by condensing the linker with Exatecan (HY-13631) and can be used to prepare antibody-drug conjugates (ADCs). MCC is an ADC linker containing a maleimide fragment.
    MCC-AAQ-Exa
  • HY-400770
    MC-GGFG-AM-(10Me-11F-Camptothecin) intermediate-1
    MC-GGFG-AM-(10Me-11F-Camptothecin) intermediate-1 (compound 19-2) is an intermediate for the synthesis of MC-GGFG-AM-(10Me-11F-Camptothecin) (HY-153360). Modifying groups can be added group. MC-GGFG-AM-(10Me-11F-Camptothecin) is a drug-linker conjugate used in the synthesis of ADCs.
    MC-GGFG-AM-(10Me-11F-Camptothecin) intermediate-1
  • HY-128943
    MAC glucuronide phenol-linked SN-38
    		99.19%
    MAC glucuronide phenol-linked SN-38 is a pH-susceptible lactone MAC glucuronide phenol-linked SN-38 (DNA topoisomerase I inhibitor) agent linker. MAC glucuronide phenol-linked SN-38 is cytotoxic across L540cy cells and Ramos cells with IC50 values of 113 and 67 ng/mL, respectively.Albumin-coupled MAC glucosidol-linked SN-38 shows good stability in mouse plasma.
    MAC glucuronide phenol-linked SN-38
Drug-Linker Conjugates for ADC Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.